Skip to main content
S&P 5007,672.69+1.07%DOW52,582.61+1.00%NASDAQ26,419.31+1.29%BTC$78,740.00+2.06%ETH$2,609.95+7.07%GOLD$4,407.400.00%OIL$99.57-2.84%
Smart Investors Daily
CA

NASDAQ · CARL

CARLSMED, INC.

Healthcare · Medical - Healthcare Information Services

$14.76

Up+$0.15 (+0.98%)

Updated Sep 11, 2026, 3:35 PM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
348.63M
P/E ratio
-10.74
Dividend yield
0.00%
52-week range
$8.50 – $17.23
Volume
59.16K
Avg. volume
96.69K

Price performance

CARL price history

1M range · 20 trading sessions · Daily adjusted prices

CARL closed at $14.76 after 20 trading sessions, up 5.50% for the selected period.

Last close
$14.76
Period change
+5.50%
Period low
$13.78
Period high
$16.88
Daily close
View OHLC price history
CARL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$14.88$15.29$14.74$14.7659.16K
Sep 9, 2026$15.19$15.86$14.93$14.9953.39K
Sep 8, 2026$15.37$15.37$15.01$15.2363.86K
Sep 4, 2026$15.38$15.88$15.38$15.6046.73K
Sep 3, 2026$16.48$16.65$15.4491$15.52158.81K
Sep 2, 2026$16.44$17.20$16.25$16.34116.02K
Sep 1, 2026$16.48$16.86$16.10$16.3787.08K
Aug 31, 2026$16.73$16.73$16.13$16.29102.68K
Aug 28, 2026$16.86$17.00$16.52$16.88121.48K
Aug 27, 2026$16.18$16.79$15.74$16.75165.16K
Aug 26, 2026$16.06$16.34$15.85$16.1880.97K
Aug 25, 2026$15.78$16.31$15.50$16.07119.49K
Aug 24, 2026$16.07$16.43$15.755$15.80114.69K
Aug 21, 2026$16.49$17.23$16.01$16.05263.74K
Aug 20, 2026$15.50$16.51$15.22$16.50419.41K
Aug 19, 2026$15.00$15.57$14.54$15.52308.6K
Aug 18, 2026$13.84$14.92$13.75$14.88290.05K
Aug 17, 2026$14.29$14.50$13.71$13.7890.07K
Aug 14, 2026$14.08$14.50$13.80$14.3276.98K
Aug 13, 2026$13.87$14.16$13.77$13.99127.4K

Latest CARL news

The latest Smart Investors Daily articles mentioning CARL.

Stock researchCompany · Overview

CARL research

Overview

Company profile and research snapshot.

Company profile

Carlsmed Inc is a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. It is focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of AI-enabled software solutions, and interbody implants that it custom design for each patient's unique pathology and vertebral bone topography, and single-use surgical instruments. The Company designs, manufactures, and markets aprevo, a comprehensive technology platform for spine fusion surgery procedures.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$18.00
Implied upside
—
Analysts
—
CARL recent ratings
DateFirmRatingTarget
Aug 6, 2026Truist SecuritiesBuy—
Jul 1, 2026NeedhamBuy—
May 6, 2026BTIGBuy—
Apr 15, 2026Truist SecuritiesBuy—
Apr 9, 2026Goldman SachsBuy—
Open full forecast

News briefing

Generated Sep 11, 2026, 3:13 PM

Why Is CARL Up Today?

Carlsmed, Inc. shares rose 1.42% today following the announcement of a new Chief Operating Officer appointment. While the market's modest positive response suggests measured optimism, investors are likely viewing this leadership move as a potential catalyst for operational improvements and strategic execution.

    Bottom line: Today's modest 1.42% gain reflects cautious market optimism about Carlsmed's appointment of a new Chief Operating Officer. While leadership changes can be positive catalysts, investors should monitor upcoming investor presentations or strategic announcements from management to assess whether this operational appointment translates into tangible business improvements and value creation.

    Yahoo · Sep 8, 2026

    Carlsmed, Inc. Announces Chief Operating Officer Appointment

    CARLSBAD, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Jeff Bertolini has been promoted to the role of Chief Operating Officer, effective immediately. Jeff joined Carlsmed in September 2024, most recently serving as the Company’s Senior Vice President, Operational Excellence and previously, Vice President of Advanced Manufacturin

    AI research layers

    Interpretive context generated from the platform’s current data sources.

    No results

    AI research layers have not been published yet.

    Featured By